PlexusDx offers oral semaglutide, compounded tirzepatide (injection and oral), GLP-Squared combination injections, and the Microdose GLP-1 Protocol
Expect oral Wegovy to be added to more formularies by: April 2026: First quarterly formulary update after launch July 2026: Most major PBMs should have coverage policies finalized Medicare Part D (July 2026 Demo January 2027 BALANCE) CMS announced a short-term demonstration starting July 2026 that will provide Medicare Part D beneficiaries access to GLP-1s for obesity at $50/month
There is one exception: if Wegovy is prescribed for a covered indication other than weight loss (the drug has a separate FDA approval for cardiovascular risk reduction in adults with established cardiovascular disease and BMI 27), some Medicare plans may cover it under that indication
Considerations and Health Benefits Tirzepatide may help you lose weight and boost your metabolism, which: Decreases the risk of heart disease Helps you regulate your blood sugar Relieves stress on your joints However, nausea, constipation, and, in rare cases, pancreatitis are possible adverse effects that need to be taken into consideration
If you dont qualify for Apple Health, you can still get other types of plans and savings
This is where things stand now. Proposed rule and public comment
